Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model

Cancer Science

Volumn 100, Issue 7, 2009, Pages 1219-1226

  Nagamachi, Akiko ^a   Yamasaki, Norimasa ^a   Miyazaki, Kazuko ^a   Oda, Hideaki ^b   Miyazaki, Masaki ^c   Honda, Zen Ichiro ^d   Kominami, Ryo ^e   Inaba, Toshiya ^a   Honda, Hiroaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HISTONE H2AX; MESSENGER RNA; PROTEIN BCL11B; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLAST CELL CRISIS; CANCER SURVIVAL; CELL LINEAGE; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; GENE LOSS; GENOTYPE; HAPLOIDY; HAPLOINSUFFICIENCY; HETEROZYGOTE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; LYMPHOCYTE CLONE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; BLAST CRISIS; CHROMOSOME ABERRATIONS; FUSION PROTEINS, BCR-ABL; HAPLOTYPES; HETEROZYGOTE; HISTONES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, TRANSGENIC; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 67449087431     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01172.x     Document Type: Article

References (24)

1. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010-22.
2. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172-83.
3. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441-53.
4. Honda H, Oda H, Suzuki T et al. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: A novel transgenic model for human Ph1-positive leukemias. Blood 1998; 91: 2067-75.
5. Honda H, Ushijima T, Wakazono K et al. Acquired loss of p53 induces blastic transformation in p210bcr/abl-expressing hematopoietic cells: A transgenic study for blast crisis of human CML. Blood 2000; 95: 1144-50.
6. Niki M, Cristofano DA, Zhao M et al. Role of Dok-1 and Dok-2 in leukemia suppression. J Exp Med 2004; 200: 1689-95.
7. Mizuno T, Yamasaki N, Miyazaki K et al. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice. Oncogene 2008; 29: 3465-74.
8. Wakabayashi Y, Watanabe H, Inoue J et al. Bcl11b is required for differentiation and survival of αβ T lymphocytes. Nat Immunol 2003; 4: 533-9.
9. Bonner WM, Redon CE, Dickey JS et al. γH2AX and cancer. Nat Rev Cancer 2008; 8: 957-67.
10. Bassing CH, Chua KF, Sekiguchi J et al. Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci USA 2002; 99: 8173-8.
11. Miyazaki K, Kawamoto T, Tanimoto K, Nishiyama M, Honda H, Kato Y. Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes. J Biol Chem 2002; 277: 47 014-21.
12. Honda H, Ohno S, Takahashi T, Takatoku M, Yazaki Y, Hirai H. Establishment, characterization, and chromosomal analysis of new leukemic cell lines derived from MT/p210bcr/abl transgenic mice. Exp Hematol 1998; 26: 188-97.
13. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 2003; 101: 673-80.
14. Bassing CH, Suh H, Ferguson DO et al. Histone H2AX: A dosage-dependent suppressor of oncogenic translocations and tumors. Cell 2003; 114: 359-70.
15. Celeste A, Difilippantonio S, Difilippantonio MJ et al. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 2003; 114: 371-83.
16. Satterwhite E, Sonoki T, Willis TG et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood 2001; 98: 3413-20.
17. Wakabayashi Y, Inoue J, Takahashi Y et al. Homozygous deletions and point mutations of the Rit1/Bcl11b gene in gamma-ray induced mouse thymic lymphomas. Biochem Biophys Res Commun 2003; 301: 598-603.
18. Albu DI, Feng D, Bhattacharya D et al. BCL11B is required for positive selection and survival of double-positive thymocytes. J Exp Med 2008; 204: 3003-15.
19. Przybylski GK, Dik WA, Wanzeck J et al. Disruption of the BCL11B gene through inv (14) (q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL. Leukemia 2005; 19: 201-8.
20. Riches LC, Lynch AM, Gooderham NJ. Early events in the mammalian response to DNA double-strand breaks. Mutagenesis 2008; 23: 331-9.
21. Kinner A, Wu W, Staudt C, Iliakis G. c-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucl Acids Res 2008; 36: 5678-94.
22. Novik KL, Spinelli JJ, Macarthur AC et al. Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007; 16: 1098-106.
23. Kamimura K, Ohi H, Kubota T et al. Haploinsufficiency of Bcl11b for suppression of lymphomagenesis and thymocyte development. Biochem Biophys Res Commun 2007; 355: 538-42.
24. Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci USA 1993; 90: 3755-9.